Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19

University Hospital, Strasbourg, France50 enrolled

Overview

Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid-19

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient over the age of 18; * Diagnostic COVID-19 by RT-PCR; * Hospitalisation in resuscitation for the management of complications related to COVID-19 * Implanted ECMO-VV or VA during hospitalisation; * Patient agreeing to participate in the study Exclusion Criteria: * Sujet who has expressed opposition to participating in the study. * Sujet under guardianship or trusteeship * Sujet under safeguard of justice

Locations (1)

Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Outcomes

Primary Outcomes

Retrospective description of effect of the ECMO-VV or ECMO-VA in the management of severe ARDS refractory in patients of the Strasbourg and Louvain centres with covid-19

Time frame: files analysed retrospectily from March 1st, 2020 to August 1st, 2020 will be examined

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.